GCM
TRDA icon

Graham Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Graham Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$246K Buy
+33,457
New +$321K ﹤0.01% 971

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Graham Capital Management's TRDA Position: Q2 2026 in Review

Graham Capital Management opened a new position in Entrada Therapeutics (TRDA) in Q2 2026: 33,457 shares worth $246K. The stake represents ﹤0.01% of the portfolio and ranks #971 among its holdings.

129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Graham Capital Management held 33,457 shares of Entrada Therapeutics worth $246K as of Q2 2026.
  • Entrada Therapeutics was a new Graham Capital Management position in Q2 2026.
  • Entrada Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #971 holding.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.